Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Formycon and Zydus sign exclusive agreement for FYB206 supply
The therapy is nearing the end of clinical development, with primary endpoint outcomes anticipated in the first quarter of 2026. Credit: Wasan Tita/Shutterstock.com.
The therapy is nearing the end of clinical development, with primary endpoint outcomes anticipated in the first quarter of 2026. Credit: Wasan Tita/Shutterstock.com.